Every 10-Q that Omada Health, Inc. (OMDA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow OMDA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OMDA filings page.
Omada Health, Inc. reported strong growth and a return to profitability for the quarter ended June 30, 2026. Total revenue was 87,835 (in thousands), up 43% year over year, driven by services revenue of 80,692 and hardware revenue of 7,143 (both in thousands). Gross profit rose to 63,787 (in thousands), and gross margin expanded to 73%. The company generated net income of 5,294 (in thousands), compared with a loss of 5,311 (in thousands) a year earlier.
For the first half of 2026, revenue grew 43% to 165,883 (in thousands), with net income of 2,324 (in thousands). Membership expanded to 1,091,000 total members as of June 30, 2026. Partners affiliated with The Cigna Group remained highly significant, each representing over 30% of revenue. Omada ended the period with cash and cash equivalents of 221,712 (in thousands) and total assets of 328,222 (in thousands), with no preferred stock or warrant liabilities outstanding, while continuing to invest in research and development and sales and marketing to support platform and membership growth.
Omada Health, Inc. reported strong first-quarter 2026 growth with a smaller loss. Revenue rose to $78.0 million, up 42% from $55.0 million a year earlier, driven by a 51% increase in average members and higher hardware shipments. Services revenue reached $69.6 million and hardware revenue $8.5 million.
Gross profit increased to $48.7 million and gross margin expanded to 62.4%, helped by efficiency initiatives in Care Team operations and supporting technology. The net loss narrowed to $3.0 million from $9.4 million, while cash and cash equivalents remained high at $211.8 million. Total members reached 1,025,000 as of March 31, 2026.
Omada Health (OMDA) reported Q3 2025 results showing strong top-line growth and improved losses. Revenue for the three months ended September 30, 2025 rose to $68.0 million from $45.5 million a year ago, driven by services revenue of $62.9 million and hardware revenue of $5.1 million. Gross profit increased to $45.1 million from $28.6 million.
Operating loss narrowed to $2.5 million from $8.5 million, and net loss improved to $3.2 million from $9.2 million. Basic and diluted net loss per share was $(0.06) (vs. $(1.18)), reflecting a larger post‑IPO share count.
Liquidity strengthened materially. Cash and cash equivalents were $198.6 million at quarter‑end (vs. $76.4 million at December 31, 2024). The company completed an IPO on June 9, 2025, generating $151.6 million in net proceeds and subsequently repaid its MidCap term loan and revolver, recording a $2.1 million loss on debt extinguishment. Accounts receivable increased to $41.4 million, with significant contributions from affiliates of The Cigna Group. Shares outstanding were 57,908,047 as of November 5, 2025.
Omada Health reported accelerating commercial growth with materially stronger liquidity following its IPO. Revenue rose to $61.4 million for the quarter and $116.3 million for the six months, increases of 49% and 52% year-over-year, driven by services and connected-device sales. Gross profit expanded while operating loss narrowed to $4.3 million for the quarter and $12.7 million for six months, reflecting higher revenue and continued investment in R&D, sales and marketing, and G&A.
The company closed an IPO that generated $151.6 million of net proceeds and converted all redeemable convertible preferred stock into common shares, leaving cash and cash equivalents of $223.1 million and eliminating prior preferred-stock balances and related warrant liabilities. Omada reported over 752,000 enrolled members and maintains a $30.0 million term facility (repaid subsequent to period). Despite improved liquidity and revenue momentum, the company remains loss-making with a substantial accumulated deficit.